SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/17/2017 1:04:22 PM - Followers: 140 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
RXII
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#4521   He's a proven turd, true, but, planned RS Full Contact Yoga 08/17/17 01:04:22 PM
#4520   5 year lows in sight...share price going in NGIN 08/17/17 11:04:53 AM
#4519   Wall Street does not trust Geert, for he BioPharma 08/16/17 09:12:17 AM
#4518   Guess time will tell. Interested parties do ZeWaffleBaron 08/15/17 10:31:40 AM
#4517   Does RXi really have interested parties which will BioPharma 08/14/17 10:08:03 PM
#4516   You have mixed up some other company with sabaidii2 08/10/17 08:28:25 PM
#4515   RXII and ECGR are my two best performers Pennybuster11 08/10/17 01:07:34 PM
#4514   Today: RXi Pharmaceuticals Granted 180-Day Extension by The Other Guy 08/03/17 09:08:46 AM
#4513   When do we find out if the 180 inrags86 08/02/17 02:27:01 AM
#4512   Was invested here about 2 years ago. Held Rubyred77 07/30/17 03:24:11 AM
#4511   They'll get the extension by having the RS Full Contact Yoga 07/15/17 11:31:37 PM
#4510   Well don't they have an extension to file? Inoviorulez 07/15/17 10:38:18 PM
#4509   Max price of .665, could happen anywhere below, Full Contact Yoga 07/15/17 04:54:23 PM
#4508   Agree with you on that IMHO! Def has NGIN 07/15/17 11:16:29 AM
#4507   Well I can teach you on that. When Inoviorulez 07/14/17 10:09:25 PM
#4506   where does it show it is pried at Inoviorulez 07/14/17 10:06:34 PM
#4505   RXI doing dilution again??? Geert told us they have BioPharma 07/14/17 07:26:54 PM
#4504   Nothing like seeing a filing setting the new Full Contact Yoga 07/14/17 05:25:46 PM
#4503   Could be. But, the unfortunate reality is that Full Contact Yoga 07/14/17 09:40:21 AM
#4502   About the dilution you are right it will Inoviorulez 07/14/17 06:06:12 AM
#4501   You are right on that front. After June Inoviorulez 07/14/17 05:59:31 AM
#4500   4) RXI-109 (dermal scarring reduction) - DOA (Dead sabaidii2 07/13/17 11:00:32 PM
#4499   A reverse split is not the problem. Money sabaidii2 07/13/17 10:55:14 PM
#4498   RXI needs shareholders approval of R/S in order BioPharma 07/13/17 09:27:01 PM
#4497   RS already approved in anticipation of not topping Full Contact Yoga 07/13/17 05:29:27 PM
#4496   If SP is not above $1 soon, RXi BioPharma 07/10/17 07:07:51 PM
#4495   Without good news like partnerships the day traders BioPharma 07/10/17 07:04:29 PM
#4494   stargazer, my compliments on the summary of RXII. The Other Guy 07/09/17 03:36:58 PM
#4493   RXII’s stock price and warrants started makin unprecedented stargazer123 07/08/17 06:32:04 PM
#4492   Nice little up day on no news. The Other Guy 07/07/17 04:36:56 PM
#4491   Wonder when Geert plans on executing the RS, Full Contact Yoga 07/06/17 01:40:54 PM
#4490   Agreed. Good news. RXI-109 continues to be on The Other Guy 06/21/17 10:31:34 AM
#4489   Good news!! senderos 06/21/17 08:42:44 AM
#4488   Yesterday the company filed S-1. I am not BioPharma 06/17/17 02:46:23 PM
#4487   RXi Pharmaceuticals Announces the Initiation of its Consumer The Other Guy 06/12/17 08:41:11 AM
#4486   Not yet, but yes when Geert decides to Full Contact Yoga 06/10/17 12:41:13 PM
#4485   Filings are out now. The Other Guy 06/09/17 06:39:36 PM
#4484   What were the results? Did we peons get Marksch1 06/09/17 01:34:49 PM
#4483   Yes. Life again. I wonder if this has The Other Guy 06/09/17 12:08:26 PM
#4482   Showing some strength today. New director on BOD? senderos 06/09/17 11:40:16 AM
#4481   Yes. Agreed. It also signals RXi is moving The Other Guy 06/07/17 08:54:45 AM
#4480   A great addition to the BOD. IMO, senderos 06/07/17 07:22:20 AM
#4479   any word on the outcome of the annual inrags86 06/06/17 01:56:04 PM
#4478   Tomorrow is shareholder meeting? Any prediction? BioPharma 06/05/17 05:23:41 PM
#4477   Shareholder rape vote on June 6...remember, do not Full Contact Yoga 06/02/17 10:03:07 AM
#4476   RXi Pharmaceuticals to Present at the 3rd Annual The Other Guy 05/23/17 01:24:59 PM
#4475   Typical fluff from a failing entity. RS Full Contact Yoga 05/19/17 09:45:57 AM
#4474   1) Anyone take note that the RXI-231 (skin-lightener) sabaidii2 05/12/17 01:11:09 PM
#4473   No. It happens to be consistent. Probably The Other Guy 05/12/17 01:01:23 PM
#4472   My point is, it's part of scheduled stock Full Contact Yoga 05/12/17 12:30:29 PM
PostSubject